Back to top
more

Cytek Biosciences (CTKB)

(Delayed Data from NSDQ)

$6.30 USD

6.30
1,208,571

+0.10 (1.61%)

Updated May 10, 2024 04:00 PM ET

After-Market: $6.30 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 80% and 2.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

by Zacks Equity Research

Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.

Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know

by Zacks Equity Research

In the most recent trading session, Cytek Biosciences, Inc. (CTKB) closed at $6.01, indicating a -0.33% shift from the previous trading day.

Cytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Cytek Biosciences (CTKB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Cytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Cytek Biosciences (CTKB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Wall Street Analysts Believe Cytek Biosciences (CTKB) Could Rally 47.61%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 47.6% upside potential for Cytek Biosciences (CTKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.

New Strong Buy Stocks for April 2nd

by Zacks Equity Research

CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Decline

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytek Biosciences, Inc. (CTKB) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for October 19th

by Zacks Equity Research

ASIX, CTKB and ERO have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2023.

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -66.67% and 6.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.64% and 2.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -100% and 19.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Encompass Health (EHC) Up 32% in 6 Months: More Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing facility count within its Inpatient Rehabilitation segment and sound liquidity position.

Here's Why Cytek Biosciences, Inc. (CTKB) is Poised for a Turnaround After Losing -16.6% in 4 Weeks

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why You Should Retain HCA Healthcare (HCA) Stock Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.

Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek

by Zacks Equity Research

Zacks.com featured highlights include: Genesco, Hertz Global, Suburban Propane, and Cytek.